Abstract
Artificial intelligence-based quantification of residual cancer burden to evaluate the impact of neoadjuvant therapy in resected pancreatic cancer in the PREOPANC randomised trial
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
